impaired reperfusion of cerebral microvessels, a process commonly referred to as no reflow. 6, 7 Hence, there seems to be a tight interplay between thrombotic and inflammatory circuits in the pathophysiology of ischemic stroke, and this thromboinflammation might become a promising druggable target. 8, 9 FTY720 is a lipophilic immunomodulatory sphingosine-1-phosphate (S1P) analog and has recently been approved for the treatment of relapsing-remitting multiple sclerosis. After phosphorylation by the sphingosine-kinase isoform 2, FTY720 acts on 4 of the 5 known S1P receptor subtypes. S1P receptors are widely expressed in the body including the central nervous system (CNS) and therefore exert pleiotropic functions. The most prominent effect of FTY720 is the reduction of peripheral lymphocyte counts by blocking the egress of lymphocytes from lymphoid organs through agonist-induced receptor internalization. 10 Given that T cells are obviously of major relevance for lesion development after cerebral ischemia, [5] [6] [7] it is reasonable to analyze the efficacy of FTY720 on stroke outcome. Indeed, FTY720 has already been evaluated in different stroke models in rodents by several groups. [11] [12] [13] [14] [15] [16] [17] Whereas most of these studies found a reduction of stroke volumes and improved neurological status after FTY720 treatment, [11] [12] [13] [14] [15] 17 the results on the modes of FTY720 action in the ischemic brain are conflicting. 11, 13, 14, 17 Putative mechanisms include (a) reduced brain inflammation, 11, 12, 14 (b) attenuation of BBB disruption, 14, 17 or (c) direct neuroprotective effects. 11, 13, 15 The present study assesses the relative contribution of these mechanisms in mouse models of brain ischemia/reperfusion injury and, for the first time, describes a direct modulation of thrombo-inflammation by FTY720.
Materials and Methods
A detailed description of the methods and supplementary figures are provided in the online-only Data Supplement.
Mice
A total of 235 C57Bl/6 (wild-type, WT) and 24 Rag1 −/− mice were used in this study. Animal experiments were approved by legal state authorities (Regierung von Unterfranken and Regierungspräsidium Darmstadt) and performed according to the recommendations for research in experimental stroke studies 18 and the current Animal Research: Reporting of In Vivo Experiments guidelines (http://www. nc3rs.org/ARRIVE).
Ischemia Model
Focal cerebral ischemia was induced in 6-to 8-week-old male mice (Harlan Winkelmann, Borchen, Germany) by 60 minutes or 90 minutes transient middle cerebral artery occlusion (tMCAO) as described. 19, 20 Mice were controlled for physiological parameters that could affect stroke outcome (Tables I and II; Figure I in the onlineonly Data Supplement). Edema-corrected infarct volumes were calculated from 2,3,5-triphenyltetrazolium chloride-stained brain slices. The Bederson score and the grip test score were used to monitor neurological function. 6 Mice were randomly assigned to the operators by an independent person not involved in data analysis. We performed surgery and evaluation of all readout parameters while being blinded to the experimental groups.
FTY720 Treatment
FTY720 (1 mg/kg body weight dissolved in 0.9% sodium chloride, Cayman Chemical, 10006292) was applied immediately before reperfusion, that is, removal of the occluding filament, by an intraperitoneal injection. An equal volume of sodium chloride (0.9%) (vehicle) served as control.
Western Blot
Immunoreactivity against fibrin(ogen) (antifibrin[ogen] pAb 1:500, antibody cross-reactive against fibrin and fibrinogen, Acris antibodies), occludin (antioccludin pAb 1:1000, Abcam), and actin (antiactin mAb 1:75.000, Dianova) in the ischemic cortices and basal ganglia was detected by Western Blot.
21

Determination of Blood-Brain Barrier Leakage
Blood-brain barrier leakage after tMCAO was quantified using the vascular tracer Evans Blue (Sigma Aldrich) and photometric measurements as described.
22
Immunohistochemistry
Cryo-embedded brain slices were stained with antibodies against CD31 (mouse anti-mouse, abcam, ab9498, 1:100) or fibrin(ogen) (rabbit anti-mouse, Acris, AP00766PU-N, 1:100). 23 Subsequently, slices were incubated with Dylight488-coupled goat anti-mouse (abcam, 96871, 1:100), AlexaFluor594 (invitrogen, A11012, 1:100), and biotinylated horse anti-mouse (vector, BA-2001, 1:100) antibody in PBS containing 1% bovine serum albumine.
For calculation of the thrombosis index, 7 the whole brain was sliced 24 hours after stroke, and hematoxylin and eosin staining was performed (slice thickness 10 µm). The number of occluded blood vessels within the ischemic hemispheres was counted in every 10th slice for FTY720-treated and untreated animals under a 40-fold magnification.
Immunofluorescence staining of hippocampal cultures was performed as described. 20 The following antibodies were used: MAP2a/b (1:100, Abcam) and Alexa Fluor 488-coupled donkey antibody recognizing rabbit IgG (1:250, Serotec). For detection of apoptosis, the In Situ Cell Death Detection Kit (Roche) was used according to the manufacturer's instructions.
Cell Separation and Flow Cytometry
For the isolation of brain-infiltrating mononuclear cells, a Percoll (GE Healthcare) density gradient (50%/30%) was used as described. 7 Myeloid immune cells and lymphocytes were incubated in fluorescenceactivated cell sorter buffer with monoclonal antibodies anti-CD4-PerCP (BD Bioscience, 553052), anti-CD8a-PE (BD Bioscience, 553032), anti-CD45R/B220-PE (BD-Pharmigen, 553089), anti-CD11b-PE (BD Bioscience, 557397), and anti-Gr1-allophycocyanin (Ly-6G and Ly-6C, BD Bioscience, RB6-8C5). Isotype controls were the following: antirat IgG2b PerCP (BD Bioscience, 550764), anti-hamster IgG1 fluorescein isothiocyanate (BD Bioscience, 553953), anti-rat IgG2a allophycocyanin (BD Bioscience, 553932), and anti-rat IgG2b PE (BD Bioscience, 556925). Cells were counted on a FACS Calibur (Becton Dickinson). For determining the number of CD4+ and CD8+ T lymphocytes within the intracranial vascular compartment, brains were harvested from nonperfused and perfused mice and analyzed by flow cytometry. The difference in T lymphocyte counts between nonperfused and perfused brains reflects the amount of T lymphocytes exclusively within the intracranial vasculature.
For flow cytometry analysis of peripheral immune cells, 200 μl of blood was harvested transcardially in heparin-coated tubes, and red blood cells were lysed using red blood cell lysis buffer (Biolegend) following the manufacturer description.
Thrombosis Assays
Platelet adhesion assays under flow conditions and intravital microscopy of thrombus formation in FeCl 3 -injured mesenteric arterioles were performed as described.
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Hippocampal Neuronal Cell Cultures
Neuronal cell cultures were obtained from C57Bl/6 mice embryos (E18) as described previously. 20 Neuronal cultures were incubated at 37°C and 5% CO 2 and maintained in culture for up to 5 to 7 days before performing the experiments. Cell viability was assessed by the In Situ Cell Death Detection Kit (TMR red, Roche) according to the manufacturer's instructions. For ischemic conditions, O 2 was restricted per incubation at 37°C in a humidified incubator with 5% CO 2 , 5% O 2 , and 90% N 2 . FTY720-phosphate (FTY-P, Santa Cruz) or vehicle control was added to the cell cultures.
Statistics
All data are given as mean±SEM except for the ordinal Bederson score and the grip test score that are depicted as scatter plots including median with the 25% percentile and the 75% percentile given in brackets in the text. Numbers of animals (n=10) necessary to detect a standardized effect size on infarct volumes ≥0.25 (FTY720-treated versus untreated mice) were calculated via a priori sample size analysis with the following assumptions: α=0.05, β=0. 
Results
FTY720 Induces Rapid and Sustained Lymphocytopenia
FTY720 mainly acts by trapping lymphocytes within their lymphoid organs through agonist-induced receptor internalization. 10 Therefore, we first assessed the total number of leukocytes and the fraction of distinct lymphocyte subsets (CD4+ T cells, CD8+ T cells) in the peripheral blood from stroked mice before administration of FTY720 (1 mg/kg body weight, intraperitoneal) as well as 3 and 24 hours afterward. Whereas the baseline leukocyte count was 5595±316/µL, leukocyte numbers decreased significantly, by ≈60%, 3 hours after FTY720 treatment (2190±736/µL; P<0.0001; Figure 
FTY720 Improves Stroke Outcome in WT Mice
Next, we assessed whether FTY720 protects from acute ischemic stroke in a clinically relevant scenario, that is when applied after the onset of stroke. C57Bl/6 WT mice were subjected to 60 minutes of tMCAO and received 1 mg/kg FTY720 immediately before reperfusion ( Figure 1A ). Stroke volumes on day 1 were significantly reduced, by ≈30%, in FTY720-treated mice compared with vehicle-treated controls (108.1±33.6 versus 78.2±29.4 mm 3 , P=0.048; Figure 1A ). Importantly, reduced stroke size also translated into improved functional outcomes as assessed by the Bederson score, reflecting the global neurological status (median 3.0 Figure 1B ).
To exclude the possibility that FTY720 simply delays ischemic brain damage rather than preventing it, we also investigated stroke volumes on day 3 after tMCAO ( Figure 1A ). Again, FTY720 treatment led to significantly smaller infarctions compared with controls mice also at that later time point, and we did not observe any relevant changes in stroke volumes between day 1 and day 3.
FTY720 Does Not Alter the Cellular Infiltrate in the Ischemic Brain
It is well established that the local postischemic inflammatory response that evolves after stroke modulates lesion development. [25] [26] [27] Therefore, we evaluated whether FTY720 alters the composition of the cellular infiltrate within the ischemic brain. Although FTY720 led to a rapid and significant reduction of leukocytes and lymphocytes in the peripheral blood ( Figure   Figure 1 . FTY720 improves stroke outcome. A, Top, Representative 2,3,5-triphenyltetrazolium chloride stains of 3 corresponding coronal brain sections of a vehicle-treated wild-type (WT) mouse and an FTY720-treated WT mouse euthanized on day 1 or 3 after transient middle cerebral artery occlusion. FTY720 was applied immediately before reperfusion, that is 1 h after stroke onset, at a dosage of 1 mg/kg. Infarcts seemed to be smaller in the groups receiving FTY720, and this could be confirmed by infarct volumetry (n=9-11/group; bottom). Note that there was no further change in infarct size in FTY720-treated animals between day 1 and day 3. B, Reduced stroke volumes after FTY720 treatment also translated into a better functional outcome on day 1 as assessed by the 
Stroke-Protective Effect of FTY720 Depends on the Induction of Lymphocytopenia but Not Direct Neuroprotection
We next sought to clarify the mechanisms underlying these stroke-protective properties of FTY720. Rag1 −/− mice lack T cells and B cells and are profoundly protected from ischemic neurodegeneration in the tMCAO model. [5] [6] [7] Therefore, Rag1 −/− mice are a useful tool to test whether FTY720 modulates stroke outcome via mechanisms that are independent of lymphocytopenia, for instance by mediating direct neuroprotection. In this experimental setup, vehicle-treated WT mice or FTY720-treated WT mice and Rag1 −/− mice were subjected to 90 minutes of tMCAO. This prolonged period of ischemia was chosen because 60 minutes of tMCAO only induces small infarctions in untreated Rag1 −/− mice on day 1, 5-7 making the detection of any additional infarct lowering effect of FTY720 difficult. Again, injection of FTY720 into WT mice immediately before reperfusion produced significantly smaller strokes (121.7±26.6 versus 75.9±29. −/− mice with or without FTY720 treatment (1 mg/kg immediately before reperfusion). Although FTY720 significantly improved stroke outcome in WT mice, it was unable to further reduce stroke volumes or to improve neurological status in T lymphocyte-deficient Rag1 −/− mice, which are protected from stroke already under naïve conditions. n=11/ group, P*<0.05, P**<0.001, n.s.=not significant, 1-way ANOVA followed by Bonferroni multiple comparison test (infarct volumes) or Kruskal-Wallis test followed by Dunns multiple comparison test (Bederson score, grip test). C, Bar graph presentation of the percentage of dead neurons under different experimental conditions (normoxia versus hypoxia (5% CO 2 , 5% O 2 , 90% N 2 ); 0 versus 10 versus 100 nmol/L FTY720-P). Hypoxia significantly increased the number of apoptotic neurons (P<0.0001), and application of FTY720-P could not prevent neuronal loss both under normoxic or hypoxic conditions. n=7 to 13/group, n.s.=non significant, 1-way ANOVA followed by Bonferroni multiple comparison test.
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), P<0.05; Figure 3A and 3B Figure 3A and 3B). This indicates that FTY720 acts beneficially in acute stroke mainly by affecting lymphocyte counts, whereas other potential modes of FTY720 action such as direct neuroprotection 11, 13, 15 are obviously of minor importance. However, one cannot definitely exclude from these experiments that the protection achieved in Rag1 −/− mice at a certain point reached a ceiling effect that did not allow observing small benefits of FTY720 that were not mediated by T lymphocytes.
To further corroborate our hypothesis that FTY720 does not protect from ischemic stroke by shielding neurons directly (neuroprotection), we performed additional experiments in neuronal cell cultures under normoxic and hypoxic conditions ( Figure 3C ). In line with our in vivo findings, FTY720 was unable to reduce neuronal cell death in vitro even when different concentrations of FTY720 were used.
FTY720 Reduces Microvascular Dysfunction and Thrombus Formation
We could recently show that in the tMCAO model in mice T lymphocytes interact with endothelial cells and platelets to induce microvascular dysfunction and capillary thrombosis. 7 Therefore, we speculated that FTY720 would be able to mitigate these processes by reducing the numbers of circulating lymphocytes and subsequently the event rate of harmful lymphocyte-endothelium-platelet interactions in the brain vasculature. Indeed, FTY720 treatment not only reduced the number of circulating T lymphocytes in the peripheral blood ( Figure IIA and IIB in the online-only Data Supplement) but also in the intracranial vascular compartment on day 1 after tMCAO (1245±786 [vehicle] versus 447±676 [FTY720], P<0.05; Figure III in the online-only Data Supplement). Here, the number of T lymphocytes present specifically in the brain vasculature was determined by counting cells from nonperfused and perfused brains of untreated mice and FTY720-treated mice and calculating the difference afterward.
In line with our hypothesis, the decline in T lymphocytes within the cerebral vasculature after FTY720 treatment resulted in less thrombus formation. Western blot analysis revealed that the amount of fibrin(ogen) on day 1 after tMCAO in the ischemic cortices of FTY720-treated mice was significantly lower compared with untreated controls (optical density in ipsilesional cortices 1.6±0.3 versus 4.1±0.9, P=0.002; Figure 4A ), whereas no significant differences were found in the basal ganglia (optical density in ipsilesional basal ganglia 1.8±0.6 versus 2.3±0.3, P=0.17; Figure 4A ). . A, Deposition of fibrin(ogen) in the ipsilateral (ipsi) or contralateral (contra) cortex or basal ganglia (BG) of vehicle-treated wild-type (WT) mice or FTY720-treated (1 mg/kg) WT mice as determined by immunoblot and densitometric quantification of the bands. Actin was used as loading control. FTY720 was applied immediately before reperfusion, and brains were analyzed on day 1 after tMCAO. n=4/group, *P<0.05, n.s.=not significant, 2-way ANOVA followed by Bonferroni multiple comparison test. AU=arbitrary units. B, Immunohistochemical localization of fibrin(ogen) in the lumina of brain microvessels (stained with the endothelial marker CD31) 24 h after transient middle cerebral artery occlusion (tMCAO) in the infarcted basal ganglia of vehicle-treated WT mice or FTY720-treated WT mice. One representative panel per group of 3 independent experiments is shown. Scale bar represents 100 µm. C, Left, Representative hematoxylin and eosin stains from the infarcted basal ganglia of vehicle-treated WT mice or FTY720-treated WT mice with (1 mg/kg immediately before reperfusion) on day 1 after tMCAO. Thrombotic vessels were abundant in control animals (arrows), whereas the microvascular patency was significantly increased in the mouse group receiving FTY720 (arrowheads), and this was confirmed by calculation of the thrombosis index (right). n=4/group, *P<0.05, unpaired, 2-tailed Student t test. Scale bar represents 100 µm. D, Reduction of intracerebral thrombosis in FTY720-treated mice improved cerebral blood flow (CBF) in the territory of the right middle cerebral artery 12 and 24 h after reperfusion compared with control mice as determined by serial laser Doppler flow measurements. No differences in CBF were detectable at baseline (before ischemia), immediately after insertion of the filament (ischemia), or immediately after removal of the filament (reperfusion). n=5/group and time point, ***P<0.0001, n.s.=not significant, 2-way ANOVA followed by Bonferroni multiple comparison test. Immunohistochemistry consistently demonstrated intravascular fibrin(ogen) deposits that occluded brain vessels in untreated mice and markedly reduced fibrin(ogen) deposits in mice treated with FTY720 ( Figure 4B ). Accordingly, histological sections of infarcted brain tissue from untreated mice showed numerous occlusions of vessel lumina ( Figure 4C ). In comparison, the microvascular patency was significantly increased in mice receiving FTY720 (thrombosis index: 16.0±1.4 versus 9.5±1.7, P=0.01).
To further address whether reduced clot formation in the FTY720 group also translates into better cerebral (re)perfusion after tMCAO, we measured the cerebral blood flow (CBF) over time in the territory of the right middle cerebral artery by Laser Doppler flowmetry. No differences in baseline CBF (before ischemia), CBF after insertion of the occluding filament (ischemia), or CBF after removal of the occluding filament (reperfusion) were observed between FTY720-treated mice and vehicle-treated mice (P>0.05), indicating comparable procedural conditions in both groups ( Figure 4D) Figure 4D ).
To exclude that FTY720 causes a general defect in platelet function that could account for the profound protection observed in ischemic stroke, we analyzed the ability of FTY720-treated mice to form stable thrombi in standardized thrombus formation assays. First, we studied platelet adhesion and aggregate formation on a collagen-coated surface in an ex vivo whole-blood perfusion system under high shear conditions (1000 s − 1). 7, 24 In this setting, platelets from naïve mice and mice treated with FTY720 adhered to collagen fibers and formed aggregates within 2 minutes that consistently grew into large thrombi ( Figure 5A ). By the end of the perfusion period, the surface area covered by platelets did not significantly differ between the groups (P>0.05; Figure 5A ). We also studied the effects of FTY720 on occlusive thrombus formation in vivo after FeCl 3 -induced injury of mesenteric arterioles. 7 No significant differences in the time to first appearance of thrombi >10 µm (not shown) or median occlusion time of damaged arterioles were observed between FTY720-treated mice and controls (P>0.05; Figure 5B ). These findings demonstrate that FTY720 application does not impair the general ability of platelets to form stable thrombi, at least in the setting of severe artificial vessel wall injury leading to the exposure of tissue factor and prothrombotic subendothelial matrix proteins. In line with these findings, no differences in platelet counts and volumes were observed between FTY720-treated mice and untreated controls (Table  II in 
FTY720 Does Not Stabilize the Blood-Brain Barrier After Stroke
BBB disruption and subsequent edema formation represent frequent causes of secondary infarct growth, and S1P receptors have been shown to be expressed at the BB barrier.
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Thus, we analyzed the consequences of FTY720 on BBB structure and function after brain ischemia. The extent of edema formation as assessed by the concentration of the vascular tracer Evans blue leaking into the brain parenchyma was similar between FTY-treated mice and vehicle-treated controls on day 1 after tMCAO (control: 23.2±5.0 ng/mg brain tissue, FTY720: 29.9±6.9 ng/mg brain tissue, P>0.05; Figure 6A ). In line with these findings, the expression of the tight junction protein occludin was unchanged in the cortices and basal ganglia of FTY720-treated compared with vehicle-treated mice (P>0.05; Figure 6B ).
Discussion
We identify herein lymphocytopenia as the key mechanism responsible for the stroke-protective properties of FTY720 in mice. The reduction of lymphocytes in the brain vasculature attenuated microvascular thrombus formation and increased CBF during the reperfusion phase after tMCAO. In contrast, mice. Finally, we did not find evidence for a BBB stabilizing or anti-inflammatory effect of S1P receptor modulation in the acute phase of stroke. By taking advantage of transgenic mouse models, we could recently show that depletion of T cells 6 or specialized T cell subsets, such as regulatory T cells (Treg), 7 dramatically protects from acute ischemic brain damage. Mechanistic studies revealed that the stroke-promoting properties of T cells and Treg do not depend on their classical immune function. Rather, T cells interact functionally with activated cerebral endothelial cells and platelets for instance via the lymphocyte functionassociated antigen-1/intercellular adhesion molecule-1 pathway. This interaction, which already occurs within a few hours after the onset of ischemia, causes microvascular dysfunction, leading to increased thrombus formation and subsequently impaired cerebral reperfusion after tMCAO (no reflow). 6, 7 The present study for the first time confirms this novel concept of T cell-induced thrombo-inflammation in stroke 8, 9 by using a pharmacological approach. FTY720 traps T lymphocytes within lymphoid organs, thereby inducing rapid and profound lymphocytopenia in the peripheral blood. 10 Importantly, FTY720 also decreased the number of T lymphocytes within cerebral blood vessels after tMCAO ( Figure III in the onlineonly Data Supplement), thereby reducing the probability of detrimental lymphocyte-endothelial cell-platelet interactions. As a consequence, less thrombi were formed in the brain, and CBF improved in the mouse group receiving FTY720. In full support of our hypothesis, a recent study reported fewer intercellular adhesion molecule-1 positive brain vessels in FTY720-treated mice after tMCAO.
14 Whether platelets carry S1P receptors or undergo activation after S1P binding is controversial 32, 33 and that is why we cannot definitely exclude direct (antithrombotic) effects of FTY720 on platelet function. However, our observation of regular clot formation and clot stability after severe artificial vessel wall injury in the presence of FTY720 argues against a direct impact of FTY720 on platelet aggregation and thrombus formation but rather suggests indirect mechanisms operating for instance through the reduction of peripheral lymphocyte counts.
FTY720 acts on the S1P receptor subtypes 1, 3, 4, and 5. Neurons express mainly S1P 1 and S1P 3 , and S1P 1 shows a widespread expression in the brain. 34 This, together with the fact that FTY720 can readily cross the BBB, 35 points towards a potential neuroprotective effect of FTY720. 36 Indeed, FTY720 restored synaptic transmission in cortico-striatal brain slice preparations from myelin oligodendrocyte glycoprotein-immunized experimental autoimmune encephalomyelitis mice via a direct influence on glutamatergic signaling. Notably, this effect was accompanied by structural protection of dendritic spines. 37 In line with these in vitro findings, mice that are deficient of the S1P 1 receptor only in neurons and astrocytes are largely protected from experimental autoimmune encephalomyelitis. 38 Although pharmacological S1P receptor modulation might mediate direct neuroprotection in models of autoimmune central nervous system inflammation, spinal cord injury, 39 or certain neurodevelopmental disorders such as Rett Syndrome, 40 the situation in ischemic stroke seems to be different. FTY720 did not protect primary neurons against glutamate excitotoxicity 14 or hypoxia (this study). The fact that FTY720 does not affect stroke outcome after permanent MCAO 16 and the inability of FTY720 to further reduce lesion size in lymphocyte-deficient Rag1 −/− mice after tMCAO (this study) likewise argues against a genuine neuroprotective mode of action.
FTY720 was unable to maintain BBB structure and function on stroke in our hands, although S1P receptors have been shown to be induced at the BBB in an ischemic environment. 30, 31 Moreover, a similar amount of immune cells including T lymphocytes invaded the ischemic brain tissue of FTY720-treated mice or control mice on day 1. Hence, the beneficial effect of FTY720 cannot be ascribed to a relief of BBB breakdown or local inflammation at least during the acute phase after an ischemic insult. Our findings are in Figure 6 . FTY720 does not stabilize the blood-brain barrier after ischemic stroke. A, Top, Representative coronal brain sections from a vehicle-treated wild-type (WT) mouse and a WT mouse treated with FTY720 (1 mg/kg immediately before reperfusion) on day 1 after transient middle cerebral artery occlusion (tMCAO) and injection of the vascular tracer Evans blue. Bottom, No significant difference in the concentration of Evans Blue leaking into the brain parenchyma was observed between the 2 groups; n=5 to 6/group, n.s.=not significant, unpaired, 2-tailed Student t test. B, Occludin protein expression in the ipsilateral (ipsi) and contralateral (contra) cortex or basal ganglia (BG) of vehicle-treated WT mice or FTY720-treated (1 mg/kg) WT mice as determined by immunoblot and densitometric quantification of the bands. Actin was used as loading control. FTY720 was applied immediately before reperfusion, and brains were analyzed on day 1 after tMCAO. n=4/group, n.s.=not significant, 2-way ANOVA followed by Bonferroni multiple comparison test. AU=arbitrary units.
by guest on April 2, 2017 http://stroke.ahajournals.org/ Downloaded from part discrepant to previous studies describing BBB stabilization and reduced transendothelial trafficking of immune cells mediated by FTY720 in cerebral ischemia and intracranial hemorrhage. 14, 16, 17, 41 The exact reasons for these contrary findings are unclear at present, but differences in the stroke models and animal species used might play a role. In particular, other doses of FTY720 than the one used here might produce different results in terms of BBB stabilization and immune cell transmigration. 13, 14 Moreover, our study only investigated the consequences of FTY720 treatment on immune cell invasion on day 1. At this early stage of infarction, the number of blood-borne immune cells present in the brain parenchyma is still low, 4 and we cannot exclude FTY720 effects on the composition of the cellular infiltrate at later time points. 12, 16 FTY720 has proven to mitigate ischemia-induced tissue damage in a clinically relevant setting also in other organs such as the liver 42 and the kidney. 43 This, together with the considerable number of positive studies on FTY720 in experimental stroke, [11] [12] [13] [14] [15] 17 suggests that pharmacological S1P receptor modulation is effective in ischemia/reperfusion injury in general. Although it is tempting to speculate that short-term treatment with FTY720 is beneficial in patients with stroke as well, one has to be cautious when transferring the findings from animal models to the human situation, in particular in the field of experimental stroke research. 44 Also, our proof-of-principle study was not designed to address translational aspects of FTY720 in stroke, that is, to mimic the clinical situation exactly, but rather wanted to clarify the to date unknown mode of FTY720 action in acute cerebral ischemia. Certainly, different FTY720 treatment intervals or dosing regimens or the use of older and comorbid animals might have produced different results. Moreover, specific side effects of FTY720 affecting, for instance, the cardiovascular system (induction of cardiac arrhythmias and increase in blood pressure) would probably hamper its use in clinical stroke. Finally, lymphocytopenia induced by FTY720 could further enhance stroke-related immunodepression that has recently been identified as a major cause of poststroke infection and mortality. 45, 46 In conclusion, lymphocytopenia and concomitant reduction of intravascular thrombo-inflammation, but not direct neuroprotection, are critical for the stroke-protective action of FTY720. Transient inhibition or short-term depletion of lymphocytes might become a novel approach to combat ischemic stroke in the future.
